Twenty-one years ago, the SLAS journals* began publication amid a thunderstorm of change. Test tubes were relics of the past; microplates and high-throughput screening were the new things. From there, the pace of scientific advancement accelerated beyond our wildest dreams. Crazy ideas like single-cell imaging and 1536-well plates became practical realities, and as the art of life sciences evolved, our journals evolved with it, providing information, insight, and guidance to fuel a new generation of scientific success.
Today our journals continue to serve as a vital resource for the SLAS life sciences discovery and technology community. To more accurately reflect the true nature of what SLAS represents and what our journals publish, it became obvious that their names needed to change. With this, I welcome you to SLAS Discovery-a new name with a new tagline (Advancing Life Sciences R&D) for the journal that scientists around the world trust and rely on to keep connected to the cutting edge of quantitative biology. Its unique editorial aims and scope remain the same:
SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.
SLAS Discovery is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. SLAS Discovery publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery is an official journal of SLAS (Society for Laboratory Automation and Screening).
SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium-throughput, or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio-and chemoinformatics). Review articles are on target biology, new paradigms in drug discovery, and advances in drug discovery technologies. The decision to update the name of our journal is the result of a healthy process of reflection and reevaluation that was undertaken in response to the 2014 SLAS Strategic Plan. Over a 2-year period, two task forces were organized to address different phases of the strategic planning process for both SLAS scientific journals.
Performance trend data were analyzed along with input gathered from journal editors, editorial board members, authors, members of the SLAS Americas Council, SLAS Europe Council, and advertisers. It was clear that the titles of the SLAS journals no longer accurately reflected the work that was being published and, as a result, were limiting their prospects for recognition and growth.
The SLAS life sciences community thrives at the intersection of discovery and technology-ranging from basic research to applied research. SLAS's two journals align directly along these axes, offering distinct yet complementary networks of knowledge.
SLAS Discovery continues to focus on advancing life sciences R&D, publishing reports of how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease; SLAS Technology continues to focus on translating life sciences innovation, publishing ways in which scientists adapt advancements in technology for scientific exploration and experimentation.
Whether you are a reader, author, reviewer, or editorial board member, you are a stakeholder whose needs, priorities, and vision define the editorial essence and excellence of this journal. We look forward to your continued partnership in the ongoing success of SLAS Discovery.
